FDA Advisory Committee Votes Against Capricor's Deramiocel for DMD

Key Facts

1The FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectiveness of Deramiocel for DMD cardiomyopathy.

2The committee vote was 3 in favor and 9 against, noting that the committee's recommendation is non-binding for the FDA.

In a move reflecting the high regulatory hurdles for rare disease treatments, an FDA advisory committee has voted against the effectiveness of Capricor Therapeutics' lead candidate. The Cellular, Tissue and Gene Therapies Advisory Committee determined that current evidence does not support the efficacy of Deramiocel for treating cardiomyopathy in Duchenne muscular dystrophy (DMD) patients. The vote concluded with 3 in favor and 9 against, though it is important to note that the committee's recommendation is non-binding for the final FDA decision.

This negative outcome serves as a significant headwind for the company, as advisory votes are critical indicators of a drug's path to market. Per market data, shares of CAPR stood at $6.57 at the close of July 28, 2026. During that session, the stock experienced volatility with a day high of $7.22 and a day low of $5.67, highlighting the sector's sensitivity to regulatory developments.

Traders should watch for price action relative to the $6.57 level (close of July 28, 2026) as the market processes the implications of this vote. While the economic calendar shows upcoming macro catalysts such as U.S. Durable Goods Orders on July 27, the primary focus for CAPR will remain on any subsequent responses from the FDA regarding the Deramiocel clinical data package.